Foyou Pharma Gets China Drug Registration Nod for Hypertension Tablets

(MT Newswires) -- China's medical products administrator granted Beijing Foyou Pharma (SHA:601089) a drug registration certificate for its candesartan cilexetil and hydrochlorothiazide tablets for hypertension, according to a Tuesday filing with the Shanghai bourse. The original manufacturer's candesartan cilexetil-hydrochlorothiazide tablets are not available in China. Takeda and AstraZeneca jointly developed the drug, the filing said. The drug is indicated for patients with blood pressures not effectively controlled by just candesartan cilexetil or hydrochlorothiazide alone, among others. Shares closed 2% higher on Tuesday.